Drug Profile
Research programme: angiogenesis inhibitors - Sanofi
Alternative Names: sFLT01; sFLT02Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors; Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 19 Nov 2009 Preclinical pharmacodynamics data in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)